Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Payables (2018 - 2025)

Quantum Biopharma's Payables history spans 8 years, with the latest figure at $3.3 million for Q4 2025.

  • On a quarterly basis, Payables fell 15.27% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 15.27% decrease, with the full-year FY2025 number at $3.3 million, down 15.27% from a year prior.
  • Payables hit $3.3 million in Q4 2025 for Quantum Biopharma, up from $2.0 million in the prior quarter.
  • Over the last five years, Payables for QNTM hit a ceiling of $7.8 million in Q4 2021 and a floor of $300549.0 in Q2 2021.
  • Historically, Payables has averaged $1.9 million across 5 years, with a median of $358549.0 in 2021.
  • Biggest five-year swings in Payables: crashed 77.17% in 2021 and later soared 557.23% in 2025.
  • Tracing QNTM's Payables over 5 years: stood at $7.8 million in 2021, then dropped by 5.15% to $7.4 million in 2022, then plummeted by 43.38% to $4.2 million in 2023, then dropped by 7.66% to $3.9 million in 2024, then decreased by 15.27% to $3.3 million in 2025.
  • Business Quant data shows Payables for QNTM at $3.3 million in Q4 2025, $2.0 million in Q3 2025, and $1.9 million in Q2 2025.